"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Paris Regional Cancer Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 10 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Paris Regional Cancer Center" #1 sponsor was "US Oncology Research" with 10 trials, followed by "Point Therapeutics" with 2 trials sponsored, "Millennium Pharmaceuticals, Inc." with 1 trials sponsored, "NSABP Foundation Inc" with 1 trials sponsored and "Novacea" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Paris Regional Cancer Center" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Paris Regional Cancer Center" are "Breast Cancer" (3 trials), "Metastatic Breast Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Androgen-independent Prostate Cancer" (1 trials) and "Carcinoma, Non-Small Cell Lung" (1 trials). Many other conditions were trialed in "Paris Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "Paris Regional Cancer Center" are "Drug" (17 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "docetaxel" (4 trials), "Carboplatin" (2 trials), "Cetuximab" (2 trials), "Docetaxel" (2 trials) and "cetuximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Paris Regional Cancer Center" are 11 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Paris Regional Cancer Center". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Paris Regional Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Paris Regional Cancer Center, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".